Used in research for the treatment of inflammatory conditions such as asthma and chronic obstructive pulmonary disease (COPD). It acts as a selective antagonist of the prostaglandin D2 receptor (DP1), helping to reduce airway inflammation and bronchoconstriction. Its development focused on modulating immune responses in the respiratory system, particularly by inhibiting the recruitment of eosinophils and other inflammatory cells. Studied primarily in preclinical models to evaluate its potential as an anti-inflammatory agent with improved specificity and fewer side effects compared to broad-spectrum therapies.